Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply. Issue 10297 (24th July 2021)

Record Type:: Journal Article
Title:: Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply. Issue 10297 (24th July 2021)
Main Title:: Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
Authors:: Horby, Peter
Staplin, Natalie
Haynes, Richard
Landray, Martin
Abstract:
Is Part Of:: Lancet. Volume 398:Issue 10297(2021)
Journal:: Lancet
Issue:: Volume 398:Issue 10297(2021)
Issue Display:: Volume 398, Issue 10297 (2021)
Year:: 2021
Volume:: 398
Issue:: 10297
Issue Sort Value:: 2021-0398-10297-0000
Page Start:: 300
Page End:
Publication Date:: 2021-07-24
Subjects:: Medicine -- Periodicals
Medicine -- Periodicals
Medicine
Medicine
Electronic journals
Periodicals
610.5
Journal URLs:: http://www.thelancet.com/ ↗
http://www.sciencedirect.com/science/journal/01406736 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S0140-6736(21)01422-7 ↗
Languages:: English
ISSNs:: 0140-6736
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5146.000000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 18309.xml